Company news
Entera Bio Ltd. news in 2025
Entera Bio Ltd.'s news releases, calls and decks from 2025, newest first.
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation
December 23, 2025
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
December 22, 2025
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference
November 18, 2025
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
November 14, 2025
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
October 23, 2025
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
October 16, 2025
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
September 15, 2025
Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
September 8, 2025
Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
August 28, 2025
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
August 8, 2025
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
July 28, 2025
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
July 8, 2025
Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
June 26, 2025
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
June 25, 2025
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
May 9, 2025
Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO
April 15, 2025
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
March 28, 2025
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
March 17, 2025
Entera Bio to Participate in Upcoming Events
February 24, 2025
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
February 19, 2025
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
January 26, 2025
Decks in 2025
- Technical Presentation (September 2025)
Technical · 19 slides · September 2025
- Technical Presentation (July 2025)
Technical · 14 slides · July 2025